OSLO, Norway, Oct. 12, 2020 /PRNewswire/ -- Targovax ASA
("Targovax" or "the Company") (OSE: TRVX), a clinical stage
immuno-oncology company developing oncolytic viruses to target
hard-to-treat solid tumors, today announce that the European Patent
Office has granted European Patent no 3293201. The patent covers
the use of ONCOS-102 in combination with checkpoint
inhibitors.
Torbjørn Furuseth, Chief Financial Officer of Targovax, said:
"We are delighted that this European patent has been granted,
further strengthening Targovax's intellectual property portfolio
covering the very important combination of ONCOS-102 and anti-PD1
checkpoint inhibitors. The oncology market is ever expanding, with
the immuno-oncology segment expected to see the largest growth in
the coming years. Securing this patent protects our innovative
oncolytic immunotherapy platform and strengthens our market
position."
In 2019 Targovax reported encouraging data from part 1 of a
trial in PD-1 checkpoint refractory melanoma. This trial examines
how ONCOS-102 reactivates the immune system of patients that have
progressed on checkpoint inhibitor treatment. The aim is to trigger
relevant T-cell production and infiltration into the tumor so that
patients who have become refractory can benefit from retreatment
with the checkpoint inhibitor. Data from part 2 of this trial is
expected later in 2020.
Targovax's lead product candidate, ONCOS-102, is a genetically
modified oncolytic adenovirus, which has been engineered to
selectively infect cancer cells and activate the immune system to
fight the cancer. ONCOS-102 is currently being tested in
mesothelioma, melanoma ovarian and colorectal cancers and has
already shown promising clinical results both as monotherapy and in
combination with chemotherapy, and checkpoint inhibitors.
CONTACT:
For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47-922-61-624
Email: renate.birkeli@targovax.com
Media and IR enquires:
Andreas
Tinglum
Corporate Communications (Norway)
Phone: +47-9300-1773
Email: andreas.tinglum@corpcom.no
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/targovax/r/targovax-granted-european-patent-for-oncos-102-in-combination-with-checkpoint-inhibitors,c3214022
View original
content:http://www.prnewswire.com/news-releases/targovax-granted-european-patent-for-oncos-102-in-combination-with-checkpoint-inhibitors-301149960.html
SOURCE Targovax